Navigation Links
Vystar Corporation Announces Agreement with Kildare Capital to Provide Investment Banking Services

ATLANTA, June 30 /PRNewswire/ -- Vystar Corporation today announced that Kildare Capital, a registered broker-dealer near Philadelphia, will provide investment banking services for the company.

Vystar Corporation is the exclusive creator of the innovative technology to produce Vytex(TM) Natural Rubber Latex (NRL). This patented technology reduces antigenic protein in natural latex products to virtually undetectable levels. Latex allergy has become an increasing concern, particularly in the healthcare industry where workers have prolonged and/or repeated contact with latex. It is estimated that as many as 17 percent of healthcare workers and three percent of the general population could have an allergic reaction to the protein in natural rubber latex. Vytex NRL reduces the levels of such proteins while maintaining the superior product qualities, like barrier protection, strength and durability, fit and comfort, positive environmental impact, and cost, in the vast array of everyday products made with natural rubber latex.

According to William Doyle, Vystar's Chief Executive Officer, the agreement with Kildare Capital is an important step in Vystar's journey to becoming a publicly traded company, and in achieving its goal of making Vytex NRL the standard source of latex and latex substitutes. "It is virtually unprecedented that an organization with the stature of Kildare Capital would come on as an investment banker for Vystar in our pre-revenue phase and prior to an initial public listing. They were attracted to our great progress towards commercializing Vytex NRL and the excellent test results achieved to date."

In the past six months, Vystar:

-- Signed a definitive toll manufacturing agreement with Revertex Malaysia, the world's largest producer of prevulcanized natural rubber lattices and postvulcanized latex compounds as well as the sole producer of evaporated natural rubber lattices;

-- Was added to Universal Capital Management's portfolio of companies for management and strategic growth resources;

-- Contracted with a U.S. manufacturer of condoms and straight-dipped gloves to develop products manufactured with Vytex NRL and in turn complete the biocompatibility tests for 510(k) submission to the U.S. Food and Drug Administration;

-- Signed almost 20 sampling agreements and evaluations with major manufacturers in the exam and surgical glove, foam, medical device, and condom industries.

According to Sean Sweeney, President of Kildare Capital, his firm was also attracted to Vystar's large market potential and strong progress. "It is not often we run across a product like Vytex NRL that has the potential to fundamentally change such a large industry in a cost effective manner. We believe this represents an attractive opportunity for long-term growth potential."

About Kildare Capital:

Kildare Capital, founded in 2000, is a registered broker-dealer and FINRA/MSRB member firm providing investment banking, institutional trading and capital introduction services for institutional investors, corporate clients, venture capitalists, entrepreneurs and financial sponsors. With demonstrated public market private equity and hedge experience, the company specializes in underwriting niche capital requirements through follow-on offerings, municipal debt and venture/growth transactions.

About Vystar Corporation:

Vystar Corporation, incorporated in 2003, is a privately funded corporation located in the Atlanta area. It is included in the portfolio of Universal Capital Management, Inc. (OTC Bulletin Board: UCMT.OB), a business development company that provides management and strategic growth resources to emerging growth companies. The company's operations have been focused substantially on early-stage research, development, testing and commercialization of the Vytex NRL process. Vystar, named a 2007 Top 10 Innovative Technology Company in Georgia by the Technology Association of Georgia (TAG), holds two U.S. patents for the Vytex(TM) NRL technology, with two additional filings pending. For more information, please visit .

Forward-looking Statements:

Certain matters discussed in this press release are "forward-looking statements." These forward-looking statements can generally be identified as such because the context of the statement will include words, such as Vystar Corporation "expects," "should," "believes," "anticipates" or words of similar import. Similarly, statements that describe Vystar's future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of Vystar as appropriate, which could cause actual results to differ materially from those currently anticipated. Although Vystar believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and Vystar does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

SOURCE Vystar Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Vystar Corporation and Revertex Malaysia Sign Vytex(TM) NRL Production Contract
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. Brooke Franchise Corporation Announces Selected July Results
4. MedThink Communications Retained by NanoBio Corporation
5. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
6. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
7. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
8. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
9. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
10. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
11. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology: